Abstract

Lundbeck to Present Data on Migraine Impact Reduction and Sustained Response with VYEPTI® (eptinezumab-jjmr) at 76th Annual Meeting of the American Academy of Neurology

Retrieved on: 
Tuesday, April 9, 2024
Health, Other Science, General Health, Clinical Trials, Research, Science, Pharmaceutical, Hypersensitivity, Anaphylaxis, Angioedema, Brain, Eptinezumab, Virtual Private LAN Service, Headache, Patient, American Academy, Interview, MD, Neurology, Migraine, Lundbeck, Quality of life, AAN, Abstract, Pharmaceutical industry

These data will be presented during an oral session at the 76th Annual Meeting of the American Academy of Neurology (AAN) taking place in Denver, Colo., and virtually from April 13-18, 2024.

Key Points: 
  • These data will be presented during an oral session at the 76th Annual Meeting of the American Academy of Neurology (AAN) taking place in Denver, Colo., and virtually from April 13-18, 2024.
  • “Our real-world data helps us better understand how individuals are uniquely impacted by migraine beyond monthly headache days.
  • We’re excited to continually partner with the migraine community to raise the bar on preventive treatment expectations.”
    VYEPTI is indicated for the preventive treatment of migraine in adults.
  • The safety and efficacy of VYEPTI has not been evaluated for use in any psychiatric conditions.

CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting

Retrieved on: 
Tuesday, April 9, 2024
Health, Surgery, Genetics, Managed Care, General Health, Cardiology, Biotechnology, Patient, International Society, Caregiver, White, Transplant, Columbia University, University, University of Colorado, Lung transplantation, Heart transplantation, Abstract, Lung, Heart, NYU Langone Health, Stanford University, University Health Network, MAS, Loyola University, Medical device

CareDx, along with study collaborators from leading transplant centers, will present cutting-edge developments that underscore the clinical significance of CareDx’s cardiothoracic portfolio.

Key Points: 
  • CareDx, along with study collaborators from leading transplant centers, will present cutting-edge developments that underscore the clinical significance of CareDx’s cardiothoracic portfolio.
  • This includes AlloSure Heart, AlloMap Heart, HeartCare, AlloSure Lung, and AiCAV (in development); featured in over 25 oral presentations, posters, and two symposia.
  • These presentations will highlight real-world applications driving advancements in heart and lung transplantation.
  • “We are proud to have a leading presence once again at this pivotal heart and lung transplant meeting.

City of Hope Scientists Present Leading-Edge Research at American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Oncology, Health, Health Technology, Genetics, Clinical Trials, Breast cancer, Survival, Immunotherapy, Health equity, Patient, Lung, City, National Cancer Institute, AGAF, Breast, MicroRNA, Pancreatic cancer, Lymphocyte, Clinical trial, Neoplasm, Therapy, Cancer, Exosome, Plasma, Colorectal cancer, Risk, Experiment, DNA, Virus, Translational Genomics Research Institute, Memory, Treatment, Cholangiocarcinoma, Pathology, Liquid biopsy, Microbiome, Recurrence, Irell & Manella, Disease, Intelligence, Molecular diagnostics, Overalls, AACR, TILS, Pancreas, Prognosis, Beckman Research Institute, Biomarker, Abdomen, Biology, Abstract, Bangladesh Technical Education Board, Data, Blood, Medical imaging

“City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.

Key Points: 
  • “City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.
  • “Cancer is complex and the breadth and diversity of research this year further underscores the talent, scientific rigor and curiosity at City of Hope,” Van den Brink added.
  • But those diagnosed when the cancer is contained to the pancreas have a 44.3% relative survival rate after five years.
  • Scientists with Translational Genomics Research Institute, part of City of Hope, also contributed to the study.

Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024

Retrieved on: 
Monday, April 8, 2024
General Health, Health, Science, Research, Oncology, Esophagus, Sensitivity, Prostate cancer, Survival rate, Patient, Lung, Exact sciences, Breast, Death, MD, Abstract, AACR, Cancer, Pancreas, Stomach, Liver, Ovary, Medical imaging

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test.

Key Points: 
  • Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test.
  • These results validate the sensitivity and specificity of the company’s multi-biomarker class approach across a broad range of cancer types, including the most aggressive cancers and cancers with no current standard of care for screening.
  • ASCEND-2 is a large, multi-center, prospective, case-control study of over 11,000 clinically characterized participants from a racially, ethnically, and geographically diverse cohort representative of the U.S. population.
  • Key findings: Results showed that in the rare instance when MCED testing detected pre-cancerous conditions in the DETECT-A study, surgical interventions prevented cancer development, and all patients were cancer-free at follow-up.

Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Critical Care Medicine (journal), PAP, Pulmonary alveolar proteinosis, AJRCCM, Abstract, American Journal, Conference, APAP, Diagnosis

The abstracts will be published in a supplement of the American Journal of Respiratory and Critical Care Medicine (AJRCCM) on May 1, 2024.

Key Points: 
  • The abstracts will be published in a supplement of the American Journal of Respiratory and Critical Care Medicine (AJRCCM) on May 1, 2024.
  • For more details about the ATS International Conference please visit https://conference.thoracic.org/index.php .
  • Pulmonary Alveolar Proteinosis (PAP): Pathophysiology, Diagnosis, and Management
    Bruce Trapnell, M.D., M.S.
  • will provide an overview of PAP, including the burden of this rare lung disease, the hallmark signs and symptoms of autoimmune PAP (aPAP), the most common form of PAP, and the path to diagnosing aPAP.

Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC Candidates TUB-030 and TUB-040 Demonstrating Superior Efficacy Profile and a Wide Therapeutic Window at the AACR Annual Meeting 2024

Retrieved on: 
Monday, April 8, 2024
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, Ovarian cancer, Translocase, 5T4, Cell, NSCLC, Adenocarcinoma, Patient, Neoplasm, Immunoglobulin G, Cancer, Cancer research, Spacecraft, Translation, Abstract, AACR, ADC, Non-small-cell lung cancer, Vaccine

Tubulis today presented comprehensive preclinical data on its two lead antibody-drug conjugate (ADC) candidates TUB-030 and TUB-040 at this year’s Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.

Key Points: 
  • Tubulis today presented comprehensive preclinical data on its two lead antibody-drug conjugate (ADC) candidates TUB-030 and TUB-040 at this year’s Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.
  • The poster presentations contained preclinical data, highlighting the ability of the two next-generation Tubutecan ADCs to create effective and durable responses even in low target-expressing tumor mouse models.
  • Tubulis is leveraging a proprietary suite of platform technologies to build a pipeline of uniquely matched ADC candidates that combine the right targeting molecule, conjugation chemistry and payload to deliver the true therapeutic value of the ADC approach.
  • The company’s lead candidates, both targeting solid tumor indications, are in late-stage preclinical testing, with TUB-040 ready for clinical evaluation.

Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Ovarian cancer, Immunotherapy, Carcinoma, Patient, SAN, Trial of the century, Abstract, CDX, AACR, PARP2, PDX, Pancreatic cancer, Safety, Stomach

P53 Y220C is the first tumor suppressor gene to enter into clinical study and has the potential to be used in combination with chemotherapy or oncogenic protein inhibitors.

Key Points: 
  • P53 Y220C is the first tumor suppressor gene to enter into clinical study and has the potential to be used in combination with chemotherapy or oncogenic protein inhibitors.
  • As an important downstream target of the STING signaling pathway, PARP7 is expected to be used in combination with immunotherapy in the future.
  • Details for the 2024 AACR abstracts are as follows:
    JAB-26766 is a potent, orally bioavailable PARP7 inhibitor with >1800-fold selectivity on PARP7 over PARP2.
  • The 2024 AACR Annual Meeting will be held in San Diego, California, U.S. from April 5th to April 10th.

Green Hills Software, STMicroelectronics and Cetitec Collaborate on Delivering Configurable In-Vehicle Communications Platform for Automotive Zonal Controllers

Retrieved on: 
Tuesday, April 9, 2024
Stellar, Cortex, OTA, Communication, Original equipment manufacturer, Memory, DME, LIN, Electronics, IDE, SDV, Abstract, ECU, Architecture, Écu, Heart, Safety, API, Ethernet, STMicroelectronics, R52

NUREMBERG, Germany, April 9, 2024 /PRNewswire/ -- Green Hills Software, the worldwide leader in embedded safety and security, together with STMicroelectronics, a global semiconductor leader serving customers across the spectrum of electronics applications, and Cetitec, a Porsche company and leading software specialist for the development of connectivity and networking system solutions, today announced a collaboration to deliver an integrated and configurable communications platform for use in zonal controllers for the centralized EE vehicle architecture of the SDV. This solution consists of Green Hills' µ-velOSity™ real-time operating system (RTOS), ST's Stellar Integration MCU platform, and Cetitec's advanced networking stacks, gateways and routing frameworks.

Key Points: 
  • This zonal-based centralized architecture has increased requirements for performance, safety and security of the zonal controllers and necessitates new in-vehicle networking solutions.
  • Based on this platform, Cetitec provides a demonstrator consisting of the Cetitec Gateway and the Cetitec Distributed Communications Framework (CDCF).
  • "Our collaboration with Cetitec and Green Hills on the Stellar platform brings safe and efficient solutions to our customers.
  • Green Hills, ST, and Cetitec will demonstrate the zonal controller solution platform at embedded world 2024, April 9-11, in the Green Hills booth #4-325 and in the ST booth #4A-148.

Findings Presented at ACC.24 Showed XARELTO® (rivaroxaban) Reduced the Risk of Clinically Significant Bleeding and Net Adverse Clinical Events or Rehospitalization

Retrieved on: 
Monday, April 8, 2024
Cardiology, Abstract, Harvard Medical School, Warfarin, NACE, Rivaroxaban, Ventricular fibrillation, Data analysis, Risk, Patient, Stroke, Research, CSB, American College, Clinical trial, PCI, Bleeding, Johnson & Johnson, Percutaneous coronary intervention, Pharmaceutical industry

NEW BRUNSWICK, N.J., April 8, 2024 /PRNewswire/ -- Johnson & Johnson announced today a new analysis of data from the PIONEER AF-PCI clinical trial demonstrating that XARELTO® (rivaroxaban) was associated with a reduced risk of clinically significant bleeding (CSB), and net adverse clinical events (NACE; a composite of clinically significant bleeding [CSB] or major adverse cardiovascular event [MACE]) or rehospitalization compared to warfarin among both elderly and non-elderly patients with nonvalvular atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), a nonsurgical procedure designed to relieve narrowing or occlusion of the coronary artery.1,2 These data were featured in an oral presentation today at the American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24) in Atlanta, Georgia (Abstract #906-04).

Key Points: 
  • "Despite advances in cardiovascular care, patients with nonvalvular AF continue to be at risk of potentially life-threatening cardiovascular events, especially older patients considered difficult to treat due to multiple factors, including age and co-morbidities," said C. Michael Gibson*, M.D., CEO, of the nonprofit Baim Institute and professor of Medicine, Harvard Medical School.
  • "A significant challenge in managing nonvalvular AF in older individuals undergoing PCI is determining a treatment that balances the prevention of stroke with the risk for bleeding.
  • Results from the PIONEER AF-PCI trial reinforce the need to continue to research this complex and fragile elderly patient population."
  • "With this new exploratory analysis at ACC.24, we're pleased to bring the latest research to healthcare providers that adds to the growing body of clinical evidence in older adults."

Laekna Announces Two Poster Presentations on Internally Discovered Drug Candidates at AACR 2024

Retrieved on: 
Monday, April 8, 2024
PARP1, Chem, MDA, Drug, Patient, Cancer, IND, Abstract, AACR, Survivor, DRF, Clinical trial, PARP, MOA, Xenotransplantation, Safety, Biology, San Diego Convention Center, Drug discovery, Medicine, Annual general meeting, PCC, Pharmaceutical industry

"After advancing LAE102, our internally discovered antibody against ActRIIA, into IND stage, Laekna continues to strengthen our internal discovery efforts, with new drug candidates emerging", said Dr. Justin Gu, Chief Scientific Officer of Laekna.

Key Points: 
  • "After advancing LAE102, our internally discovered antibody against ActRIIA, into IND stage, Laekna continues to strengthen our internal discovery efforts, with new drug candidates emerging", said Dr. Justin Gu, Chief Scientific Officer of Laekna.
  • Laekna will continue our internal effort of discovery novel drug candidates to provide more options for patients."
  • The company has internally discovered 14 drug candidates, among which seven have been optimized and advanced to PCC (pre-clinical candidate) stage.
  • The Annual Meeting of AACR is set for April 05 to 10, 2024 at the San Diego Convention Center, California, USA.